Related Experiment Video
Updated: Oct 13, 2025

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
Published on: August 8, 2025
Perioperative Management of Hepatitis C in Patients Undergoing Total Joint Arthroplasty
Phillip E Ross1, Joseph R Young, Casey M O'Connor
1Department of Orthopaedic Surgery, Albany Medical Center, Albany, New York.
Insights
Treating hepatitis C virus (HCV) before total joint arthroplasty (TJA) is recommended for patients with HCV. Preoperative HCV treatment improves outcomes and reduces long-term healthcare costs, despite initial higher expenses.
Area of Science:
- Orthopedic Surgery
- Infectious Diseases
- Hepatology
Background:
- Hepatitis C virus (HCV) infection is an increasing concern for total joint arthroplasty (TJA) candidates.
- HCV is a significant risk factor for periprosthetic joint infections, which have poor patient outcomes.
- Traditional HCV treatments (interferon and ribavirin) had limitations due to adverse events and inconsistent efficacy.
Purpose of the Study:
- To recommend preoperative treatment for HCV in TJA candidates.
- To highlight the challenges and benefits of managing HCV in this patient population.
- To emphasize the long-term cost-effectiveness of HCV treatment before elective TJA.
Main Methods:
- Review of current literature on HCV management in TJA candidates.
- Analysis of treatment outcomes and associated costs.
- Discussion of multidisciplinary care approaches for optimizing patient care.
Main Results:
- Direct-acting antivirals (DAAs) offer improved efficacy and tolerability over older HCV therapies.
- Barriers to DAA treatment include financial burdens and inconsistent insurance coverage.
- Multidisciplinary care is essential for addressing the complex medical, economic, and psychosocial needs of TJA candidates with HCV.
Conclusions:
- Preoperative HCV management is crucial for improving TJA outcomes and reducing infection risk.
- While upfront costs for HCV treatment are higher, it leads to reduced long-term patient morbidity and healthcare expenditures.
- Optimizing HCV treatment in TJA candidates requires a comprehensive, multidisciplinary approach.
»:
A small yet growing subset of total joint arthroplasty (TJA) candidates are diagnosed with the hepatitis C virus (HCV), which is a known risk factor for periprosthetic joint infections. Given the poor outcomes associated with TJA infection, we recommend that candidates with HCV receive treatment prior to elective TJA.
»:
Interferon and ribavirin have historically been the standard treatment regimen for the management of HCV; however, adverse events and an inconsistent viral response have limited the efficacy of these therapies. The advent of direct-acting antivirals has resolved many of the issues associated with interferon and ribavirin regimens.
»:
Despite the success of direct-acting antivirals, there are still barriers to seeking treatment for TJA candidates with HCV. Many patients are faced with financial burdens, as insurance coverage of direct-acting antiviral therapies is inconsistent and varies by the patient's state of residence and specific treatment regimen.
»:
TJA candidates with HCV present health-care providers with a unique set of challenges, often encompassing economic, psychosocial, and complex medical concerns. Multidisciplinary care teams can be beneficial when caring for and optimizing this patient cohort.
»:
Management of HCV prior to elective TJA is associated with higher up-front costs but ultimately reduces long-term patient morbidity as well as associated direct and indirect health-care expenditures.
Related Concept Videos
Peripheral Artery Disease V: Postoperative Nursing Management
Pericarditis IV: Nursing Management
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Kidney Transplant III: Nursing Management
Pericarditis III: Medical Management
Kidney Transplant II: Surgical Procedure

